论文部分内容阅读
目的:应用实时三维超声技术(RT3DE)评价表柔比星联合化疗患者左心室的收缩功能,观察左室心肌收缩同步性。方法:化疗前及化疗3个周期(63~84 d)后,对表柔比星联合化疗患者(EPI组)及正常人(对照组)进行实时三维超声心动图检查。结果:EPI组左室壁16节段、12节段收缩末期最小容积时间(Tmsv)的标准差和最大差值(即Tmsvl6-SD,Tmsvl6-dif,Tms-vl2-SD,Tmsvl2-Dif)及其心率校正值,均高于对照组,P<0.05;而化疗前与正常对照组相比上述各指标差异无统计学意义,P>0.05。结论:表柔比星联合化疗患者在常规LVEF检查未发现异常的情况下,应用三维成像技术可早期发现左室心肌收缩同步性的异常。
Objective: To evaluate the systolic function of left ventricle in epirubicin combined with chemotherapy by real-time three-dimensional ultrasound (RT3DE) and to observe the systolic synchrony of left ventricular myocardium. Methods: Real-time three-dimensional echocardiography was performed on epirubicin combined with chemotherapy (EPI group) and normal people (control group) before chemotherapy and 3 cycles of chemotherapy (63-84 days). Results: The standard deviation and the maximum difference (Tmsvl6-SD, Tmsvl6-dif, Tmsvl2-SD, Tmsvl2-Dif) of the Tmsv of the 16 segments and the 12 segments of the left ventricular wall in the EPI group and The heart rate correction values were higher than the control group, P <0.05; and before chemotherapy compared with the normal control group there was no significant difference in the above indicators (P> 0.05). Conclusion: In patients with epirubicin combined with chemotherapy, LVEF examination found no abnormalities, the application of three-dimensional imaging can be early detection of left ventricular systolic synchronic abnormalities.